Clinical Trial Results:
A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered twice daily
delivered by the Respimat® inhaler for four weeks versus placebo in patients with moderate persistent asthma
Summary
|
|
EudraCT number |
2009-018006-21 |
Trial protocol |
DE LV EE CZ AT |
Global completion date |
19 Aug 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 May 2016
|
First version publication date |
06 May 2015
|
Other versions |
|
Summary report(s) |
205.420 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.